MWNA
ALT icon

Marshall Wace North America’s Altimmune ALT Stock Holding History

Marshall Wace North America’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$8.95M Buy
+791,606
New +$9.63M 0.04% 379

Other funds holding ALT

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Marshall Wace North America's ALT Position: Q3 2021 in Review

Marshall Wace North America opened a new position in Altimmune (ALT) in Q3 2021: 791,606 shares worth $8.95M. The stake represents 0.04% of the portfolio and ranks #379 among its holdings.

119 funds tracked by Wall St. Rank hold ALT as of Q3 2021.

  • Marshall Wace North America held 791,606 shares of Altimmune worth $8.95M as of Q3 2021.
  • Altimmune was a new Marshall Wace North America position in Q3 2021.
  • Altimmune made up 0.04% of Marshall Wace North America's portfolio in Q3 2021, its #379 holding.
  • 119 funds tracked by Wall St. Rank held Altimmune as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.